Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma

NCT00400816 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT00400816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00400816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
January 6, 2016
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, central nervous system tumors